Autor segons l'article: Urpi-Sarda M, Almanza-Aguilera E, Llorach R, Vázquez-Fresno R, Estruch R, Corella D, Sorli JV, Carmona F, Sanchez-Pla A, Salas-Salvadó J, Andres-Lacueva C
Departament: Bioquímica i Biotecnologia
Autor/s de la URV: Salas Salvadó, Jorge
Paraules clau: Type 2 diabetes Prevention Predimed Prediction Population Phenotype Nmr Multi-metabolite signature Mortality Metabotypes Metabolomics Gut microbiota Disease Diet Cardiovascular risk predimed nmr multi-metabolite signature metabotypes metabolomics
Resum: To characterize the urinary metabolomic fingerprint and multi-metabolite signature associated with type 2 diabetes (T2D), and to classify the population into metabotypes related to T2D.A metabolomics analysis using the 1H-NMR-based, non-targeted metabolomic approach was conducted to determine the urinary metabolomic fingerprint of T2D compared with non-T2D participants in the PREDIMED trial. The discriminant metabolite fingerprint was subjected to logistic regression analysis and ROC analyses to establish and to assess the multi-metabolite signature of T2D prevalence, respectively. Metabotypes associated with T2D were identified using the k-means algorithm.A total of 33 metabolites were significantly different (P<0.05) between T2D and non-T2D participants. The multi-metabolite signature of T2D comprised high levels of methylsuccinate, alanine, dimethylglycine and guanidoacetate, and reduced levels of glutamine, methylguanidine, 3-hydroxymandelate and hippurate, and had a 96.4% AUC, which was higher than the metabolites on their own and glucose. Amino-acid and carbohydrate metabolism were the main metabolic alterations in T2D, and various metabotypes were identified in the studied population. Among T2D participants, those with a metabotype of higher levels of phenylalanine, phenylacetylglutamine, p-cresol and acetoacetate had significantly higher levels of plasma glucose.The multi-metabolite signature of T2D highlights the altered metabolic fingerprint associated mainly with amino-acid, carbohydrate and microbiota metabolism. Metabotypes identified in this patient population could be related to higher risk of long-term cardiovascular events and therefore require further studies. Metabolomics is a useful tool for elucidating the metabolic complexity and interindividual variation in T2D towards the development of stratified precision nutrition and medicine. Trial registration at www.controlled-trials.com: ISRCTN35739639.Copyright © 2018 Elsevier Masson SAS. All rights reserved.
Àrees temàtiques: Saúde coletiva Medicine (miscellaneous) Medicina ii Medicina i Internal medicine General medicine Endocrinology, diabetes and metabolism Endocrinology & metabolism Endocrinology Educação física Ciências biológicas ii Ciências biológicas i
Accès a la llicència d'ús: https://creativecommons.org/licenses/by/3.0/es/
ISSN: 03381684
Adreça de correu electrònic de l'autor: jordi.salas@urv.cat
Identificador de l'autor: 0000-0003-2700-7459
Data d'alta del registre: 2024-04-20
Versió de l'article dipositat: info:eu-repo/semantics/acceptedVersion
Referència a l'article segons font original: Diabetes & Metabolism. 45 (2): 167-174
Referència de l'ítem segons les normes APA: Urpi-Sarda M, Almanza-Aguilera E, Llorach R, Vázquez-Fresno R, Estruch R, Corella D, Sorli JV, Carmona F, Sanchez-Pla A, Salas-Salvadó J, Andres-Lacue (2019). Non-targeted metabolomic biomarkers and metabotypes of type 2 diabetes: A cross-sectional study of PREDIMED trial participants.. Diabetes & Metabolism, 45(2), 167-174. DOI: 10.1016/j.diabet.2018.02.006
URL Document de llicència: https://repositori.urv.cat/ca/proteccio-de-dades/
Entitat: Universitat Rovira i Virgili
Any de publicació de la revista: 2019
Tipus de publicació: Journal Publications
Repositori URV